Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company dedicated to the advent of optical biopsy. The company researches, develops and markets innovative tools to visualize and detect cellular abnormalities during endoscopic procedures. Its flagship product, Cellvizio®, a probe-­based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers high-­resolution cellular views of tissue inside the body. Large, international, multi-center clinical trials have demonstrated Cellvizio's ability to help physicians more accurately detect early forms of disease and make treatment decisions immediately. Designed to improve patient outcomes and reduce costs within a hospital, Cellvizio can be used with almost any endoscope. Cellvizio has 510(k) clearance from the U.S. Food and Drug Administration and the European CE-­‐Mark for use in the GI tract, biliary and pancreatic ducts and lungs.
Type
Public
HQ
Paris, FR
Founded
2000
Employees
83 (est)
Mauna Kea Technologies was founded in 2000 and is headquartered in Paris, FR

Mauna Kea Technologies Locations

Paris, FR
Cambridge, US

Mauna Kea Technologies Metrics

Mauna Kea Technologies Summary

Market capitalization

€49.4 M

Closing share price

€3.09
Mauna Kea Technologies's latest market capitalization is €49.4 M.

Mauna Kea Technologies Market Value History

Mauna Kea Technologies Online Presence

Mauna Kea Technologies News

Mauna Kea Technologies Company Life